Aaron Galaznik

630 total citations
43 papers, 460 citations indexed

About

Aaron Galaznik is a scholar working on Hematology, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Aaron Galaznik has authored 43 papers receiving a total of 460 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Hematology, 12 papers in Pathology and Forensic Medicine and 11 papers in Oncology. Recurrent topics in Aaron Galaznik's work include Lymphoma Diagnosis and Treatment (12 papers), Acute Myeloid Leukemia Research (9 papers) and Chronic Lymphocytic Leukemia Research (6 papers). Aaron Galaznik is often cited by papers focused on Lymphoma Diagnosis and Treatment (12 papers), Acute Myeloid Leukemia Research (9 papers) and Chronic Lymphocytic Leukemia Research (6 papers). Aaron Galaznik collaborates with scholars based in United States, Japan and United Kingdom. Aaron Galaznik's co-authors include Kelly H. Zou, Jill A. Bell, Yaping Shou, Augustina Ogbonnaya, Michael Eaddy, Xuemei Luo, Vera J. Stecher, John P. Mulhall, Vicki A. Morrison and Douglas V. Faller and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Aaron Galaznik

40 papers receiving 450 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Aaron Galaznik United States 13 134 121 94 88 74 43 460
Erika Brown United States 12 71 0.5× 80 0.7× 43 0.5× 51 0.6× 136 1.8× 40 706
Ravi Potluri United States 13 300 2.2× 69 0.6× 41 0.4× 272 3.1× 196 2.6× 77 774
I. Gilloteau United States 18 200 1.5× 101 0.8× 123 1.3× 160 1.8× 53 0.7× 48 998
Anna C. Beck United States 15 208 1.6× 59 0.5× 99 1.1× 22 0.3× 92 1.2× 72 705
K Malottki United Kingdom 11 59 0.4× 63 0.5× 30 0.3× 77 0.9× 50 0.7× 17 725
Jonathan R. Korn United States 17 141 1.1× 334 2.8× 78 0.8× 80 0.9× 96 1.3× 37 855
H. Irving Pierce United States 14 244 1.8× 127 1.0× 58 0.6× 70 0.8× 41 0.6× 22 834
Dominique Lejeune United States 14 106 0.8× 49 0.4× 24 0.3× 35 0.4× 37 0.5× 64 570
Huah Shin Ng Australia 14 162 1.2× 167 1.4× 60 0.6× 12 0.1× 71 1.0× 36 548
Karen Lin United States 13 212 1.6× 62 0.5× 39 0.4× 47 0.5× 49 0.7× 22 612

Countries citing papers authored by Aaron Galaznik

Since Specialization
Citations

This map shows the geographic impact of Aaron Galaznik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aaron Galaznik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aaron Galaznik more than expected).

Fields of papers citing papers by Aaron Galaznik

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aaron Galaznik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aaron Galaznik. The network helps show where Aaron Galaznik may publish in the future.

Co-authorship network of co-authors of Aaron Galaznik

This figure shows the co-authorship network connecting the top 25 collaborators of Aaron Galaznik. A scholar is included among the top collaborators of Aaron Galaznik based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aaron Galaznik. Aaron Galaznik is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zou, Kelly H., et al.. (2024). The Next Horizon of Drug Development: External Control Arms and Innovative Tools to Enrich Clinical Trial Data. Therapeutic Innovation & Regulatory Science. 58(3). 443–455. 4 indexed citations
2.
Galaznik, Aaron, et al.. (2021). PIN83 The COVID-19 Research Database: Building One of the Largest PRO Bono Real-World DATA Repositories. Value in Health. 24. S121–S121. 3 indexed citations
3.
McLean, Catriona, J. Ransom, & Aaron Galaznik. (2019). PCN432 EVALUATION OF MISSING DATA IMPUTATION STRATEGIES IN CLINICAL TRIAL AND EMR DATA USING STANDARDIZED DATA MODELS. Value in Health. 22. S520–S520. 1 indexed citations
4.
Bell, Jill A., Aaron Galaznik, Farrah Pompilus, et al.. (2019). A pragmatic patient-reported outcome strategy for rare disease clinical trials: application of the EORTC item library to myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. Journal of Patient-Reported Outcomes. 3(1). 35–35. 10 indexed citations
5.
6.
Galaznik, Aaron, et al.. (2019). PMU8 A SYSTEMATIC APPROACH FOR SYNTHETIC REPLICATION OF CLINICAL TRIAL COHORTS USING RETROSPECTIVE REAL-WORLD AND CLINICAL TRIAL DATA. Value in Health. 22. S250–S250. 1 indexed citations
7.
Morrison, Vicki A., Yaping Shou, Jill A. Bell, et al.. (2019). Treatment Patterns and Survival Outcomes in Patients With Follicular Lymphoma: A 2007 to 2015 Humedica Database Study. Clinical Lymphoma Myeloma & Leukemia. 19(4). e172–e183. 16 indexed citations
8.
Ren, Jinma, Carl V. Asche, Yaping Shou, & Aaron Galaznik. (2019). Economic burden and treatment patterns for patients with diffuse large B-cell lymphoma and follicular lymphoma in the USA. Journal of Comparative Effectiveness Research. 8(6). 393–402. 24 indexed citations
9.
Galaznik, Aaron, et al.. (2019). Predicting Outcomes in Patients With Diffuse Large B-Cell Lymphoma Treated With Standard of Care. Cancer Informatics. 18. 2411581842–2411581842. 4 indexed citations
10.
11.
Bell, Jill A., et al.. (2018). P3.15-03 Capturing the Patient Experience for the Treatment of EGFR Exon 20 Mutations in Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 13(10). S991–S992. 1 indexed citations
12.
Bell, Jill A., Aaron Galaznik, Marlo Blazer, et al.. (2018). Economic Burden of Patients Treated for Higher-Risk Myelodysplastic Syndromes (HR-MDS) in Routine Clinical Care in the United States. PharmacoEconomics - Open. 3(2). 237–245. 14 indexed citations
13.
Bell, Jill A., et al.. (2018). Systematic Literature Review of Treatment Options and Clinical Outcomes for Patients With Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia. Clinical Lymphoma Myeloma & Leukemia. 18(4). e157–e166. 11 indexed citations
14.
15.
16.
17.
Galaznik, Aaron, Jill A. Bell, Michael E. Stokes, et al.. (2016). Systematic Review of Therapy Used in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Blood. 128(22). 3562–3562. 1 indexed citations
18.
Hyde, Craig, Shaum Kabadi, Vinícius Bonato, et al.. (2016). Utilization of Positive and Negative Controls to Examine Comorbid Associations in Observational Database Studies. Medical Care. 55(3). 244–251. 17 indexed citations
19.
Suehs, Brandon T., et al.. (2014). Association of Out-of-Pocket Pharmacy Costs with Adherence to Varenicline. Journal of Managed Care Pharmacy. 20(6). 592–600. 14 indexed citations
20.
Joshi, Ashish V., et al.. (2013). Potential impact of immediate release opioid analgesics with tamper resistant technologies on abuse treatment and drug acquisition costs. Value in Health. 16(3). A115–A115. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Erika Brown Breakdown of academic impact, for papers by Ravi Potluri Breakdown of academic impact, for papers by I. Gilloteau Breakdown of academic impact, for papers by Anna C. Beck Breakdown of academic impact, for papers by K Malottki Breakdown of academic impact, for papers by Jonathan R. Korn Breakdown of academic impact, for papers by H. Irving Pierce Breakdown of academic impact, for papers by Dominique Lejeune Breakdown of academic impact, for papers by Huah Shin Ng Breakdown of academic impact, for papers by Karen Lin
Rankless by CCL
2026